Karius said today its next-generation sequencing (NGS) plasma test for pathogen detection will be used by Nohla Therapeutics will use in its Phase II trial evaluating the company’s lead product, NLA101, in acute myeloid leukemia (AML) patients with chemotherapy-induced neutropenia.

The value of the clinical collaboration was not disclosed.

Karius will provide lab testing and analysis services to support Nohla’s Phase II trial (NCT03301597). Karius’ Digital Culture™ Test for infectious diseases is designed to detect microbial cell-free DNA (cfDNA) in plasma from more than 1,000 pathogens from a single blood draw in one day using NGS—including bacteria, DNA viruses, fungi and protozoa.

The test is intended to enable clinicians, and biopharmas to easily monitor immunocompromised patients for infections. Results are typically available within one day of sample receipt, according to Karius.

The Karius test provides a quantitative assessment of pathogen DNA in both clinically-documented infections and subclinical infections. Nohla is using the Karius test to assess infections in adult patients with chemotherapy-induced neutropenia who have received NLA101, a universal, off-the-shelf stem and progenitor cell therapy designed to provide short-term hematopoietic recovery, with the potential for long term immunologic and clinical benefits.

“Our comprehensive platform for pathogen detection covers a broad range of over a thousand bacteria, DNA viruses, and eukaryotic pathogens including yeasts and molds,” Karius Medical Director David K. Hong, M.D., said in a statement. “We are excited to work with Nohla as they advance patient care in patients with hematological malignancies.”

Added Colleen Delaney, M.D., Nohla founder and CMO: “The Karius Next Generation Sequencing cell-free microbial DNA test will augment our Phase II clinical trial and allow us to evaluate how NLA101 can potentially prevent infections in neutropenic acute myeloid leukemia patients receiving high dose chemotherapy.”

News & FeaturesAcute myeloid leukemiaCancersCellular, Molecular and Developmental BiologyClinical drug developmentClinical medicineDNA sequencing (Sequencing)Drug development (Research and development)Health care and economicsHealth care facility, manpower, and servicesHealth care servicesHematologic and lymphatic cancerHematologic diseasesLeukemiaLeukocyte disordersMedicineMedicine, Diagnosis, and TherapeuticsMolecular biologyNeutropeniaNext-generation sequencing (Sequencing)Nucleic acid sequencingPatient carePhase II clinical trials (Drug development)Precision medicineResearch and developmentSequencingSystemic conditionsNohla
Also of Interest
NCCN and Flatiron Health Extend Collaboration to Improve Cancer Care Quality with Real-World Data
Genialis Uses Machine Learning to Personalize Cancer Treatment Outcomes 
Liquid Biopsy: A New Frontier in Small-Cell Lung Cancer Management
BillionToOne Taps Culmination Bio to Validate Oncology Diagnostics
APOBEC Inhibition Timing Critical to Prevent New Mutations
Enhertu Becomes First Tumor Agnostic HER2-Targeted Treatment Approved